ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility
Aug 20
2021
American Society of Hematology. (2021).
ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility.
American Society of Hematology.
"ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility
(label-accessed April 20, 2024).
"American Society of Hematology."
ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility, 20 Apr. 2024 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility.
